Compare Moderna, Inc. (MRNA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Atlassian Corporation PLC — how do they compare? Moderna, Inc. trades at $64.17 (market cap $24.18B), while Atlassian Corporation PLC trades at $153.07 (market cap $39.10B). The key difference: Atlassian Corporation PLC is the larger of the two by market cap. Which is the better fit depends on your goals.
| MRNA | TEAM | |
|---|---|---|
Market Cap | $24.18B | $39.10B |
Sector | Health | Technology |
52-Week High | $81.80 | $182.36 |
52-Week Low | $22.36 | $57.15 |
Enterprise Value | $20.33B | $39.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Atlassian (TEAM) trades at $152.49, up 0.41% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported strong Q4 2026 earnings, beating estimates with 28% revenue growth and achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a consensus price target of $161.93.
The outlook is favorable given accelerating cloud revenue and AI platform adoption, though risks include high valuation multiples and potential growth deceleration. Net losses have narrowed significantly, but the stock's EV/EBITDA of 184.26 suggests premium pricing. Continued execution on enterprise deals and margin expansion are key for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
